Company Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.
The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache.
It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
| Country | United States |
| Founded | 1876 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 47,000 |
| CEO | David Ricks |
Contact Details
Address: Lilly Corporate Center Indianapolis, Indiana 46285 United States | |
| Phone | 317 276 2000 |
| Website | lilly.com |
Stock Details
| Ticker Symbol | LLY |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000059478 |
| CUSIP Number | 532457108 |
| ISIN Number | US5324571083 |
| Employer ID | 35-0470950 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David A. Ricks | Chairman, Chief Executive Officer and President |
| William F. Heath Jr., Ph.D. | Group Vice President of Medicines Innovation Hub - Lilly Research Laboratories |
| Kevin Hern | Vice President of Investor Relations |
| Kim Macko | Senior Director of Research & Development Strategy and Transformation |
| Jeffrey Emmick M.D., Ph.D. | Vice President of Diabetes Product Development |
| Andrew Adams Ph.D. | Vice President of New Therapeutic Modalities and Scientific Leader |
| James Croaning | Global Brand Development Leader - Diabetes |
| Sara Smith | Director of Investor Relations |
| Dr. Mark A. Mintun M.D. | Vice-President of Pain and Neurodegeneration Research & Clinical Development |
| John Sims | Senior Medical Director of Neurodegeneration |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 21, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 21, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 13, 2025 | 144 | Filing |
| Mar 7, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 3, 2025 | 144 | Filing |
| Feb 25, 2025 | 144 | Filing |
| Feb 19, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 19, 2025 | 10-K | Annual Report |
| Feb 13, 2025 | 144 | Filing |
| Feb 12, 2025 | 8-K | Current Report |